Show simple item record

dc.contributor.authorAmeratunga, M
dc.contributor.authorKipps, E
dc.contributor.authorOkines, AFC
dc.contributor.authorLopez, JS
dc.date.accessioned2018-11-14T09:10:48Z
dc.date.issued2019-01
dc.identifier.citationClinical cancer research : an official journal of the American Association for Cancer Research, 2019, 25 (1), pp. 21 - 28
dc.identifier.issn1078-0432
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2924
dc.identifier.eissn1557-3265
dc.identifier.doi10.1158/1078-0432.ccr-18-1999
dc.description.abstractDysregulation of cell division resulting in aberrant cell proliferation is a key hallmark of cancer, making it a rational and important target for innovative anticancer drug development. Three selective cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors are FDA and European Medicines Agency (EMA) approved for hormone receptor-positive/HER2-negative advanced breast cancer. A major emerging appreciation is that these inhibitors not only are cytostatic, but also play critical roles in the interaction between tumor cells and the host immune response. However, to trigger an effective immune response, lymphocytes must also proliferate. This review aims to assimilate our emerging understanding on the role of CDK4/6 inhibitors in cell-cycle control, as well as their biological effect on T cells and other key immune cells, and the confluence of preclinical evidence of augmentation of anticancer immunity by these drugs. We aim to provide a framework for understanding the role of the cell cycle in anticancer immunity, discussing ongoing clinical trials evaluating this concept and challenges for developing rational combinations with immunotherapy.
dc.formatPrint-Electronic
dc.format.extent21 - 28
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://www.rioxx.net/licenses/under-embargo-all-rights-reserved
dc.subjectT-Lymphocytes
dc.subjectHumans
dc.subjectBreast Neoplasms
dc.subjectAntineoplastic Agents
dc.subjectEnzyme Inhibitors
dc.subjectCell Proliferation
dc.subjectFemale
dc.subjectCyclin-Dependent Kinase 4
dc.subjectCyclin-Dependent Kinase 6
dc.titleTo Cycle or Fight-CDK4/6 Inhibitors at the Crossroads of Anticancer Immunity.
dc.typeJournal Article
dcterms.dateAccepted2018-09-12
rioxxterms.versionofrecord10.1158/1078-0432.ccr-18-1999
rioxxterms.licenseref.urihttps://www.rioxx.net/licenses/under-embargo-all-rights-reserved
rioxxterms.licenseref.startdate2019-01
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfClinical cancer research : an official journal of the American Association for Cancer Research
pubs.issue1
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine (de Bono Prostate)
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine (de Bono Prostate)
pubs.publication-statusPublished
pubs.volume25
pubs.embargo.termsNot known
icr.researchteamMedicine (de Bono Prostate)en_US
dc.contributor.icrauthorLopez, Juanitaen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record